x

Posted 08 June, 2023

Satsuma Pharmaceuticals, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:STSA in a 8-K filed on 08 June, 2023.


  Immediately following the Effective Time, (i) John Kollins ceased serving as President and Chief Executive Officer of the Company, and (ii) Tom O'Neil ceased serving as Chief Financial Officer of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Satsuma Pharmaceuticals, Inc.
None • None
None
Market Cap
N/A
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 


Upon completion of the Merger on June 8, 2023, Ryoichi Nagata, Shuichi Kanazashi, Shunji Haruta and Akihisa Mori became the members of the Company's board of directors, and Ken Takanashi remained a member of the Company's board of directors. Accordingly, each of John Kollins, Elisabeth Sandoval Little, Heath Lukatch, Michael Riebe, Mutya Harsch, Rajeev Shah, Thomas B. King and Tom Soloway ceased serving as members of the Company's board of directors at the Effective Time. These departures were solely in connection with the Merger and not a result of any disagreement with the Company, its management or its board of directors. 


Immediately following the Effective Time, (i) John Kollins ceased serving as President and Chief Executive Officer of the Company, and (ii) Tom O'Neil ceased serving as Chief Financial Officer of the Company. Immediately following the Effective Time, each of the following persons was appointed to the position within the Company opposite their name: (a) Ryoichi Nagata - President, and (b) Shinji Nitanda - Secretary.